Ratings by Leerink (Jonathan Chang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/4/2026 | Nanobiotix S.A | NBTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Replimune Group | REPL | Downgrade | Market Perform (Outperform) |
4.76 (10.19) |
114.08% | Details | |
| 4/1/2026 | Nanobiotix S.A | NBTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | Karyopharm Therapeutics | KPTI | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/3/2026 | Akoustis Technologies | AKTS | New Coverage | Outperform (N/A) |
21.98 (24.09) |
9.6% | Details | |
| 12/8/2025 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2025 | Immatics | IMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2025 | Nanobiotix S.A | NBTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Mersana | MRSN | Downgrade | Market Perform (Outperform) |
8.87 (29.08) |
227.85% | Details | |
| 10/20/2025 | Replimune Group | REPL | Upgrade | Outperform (Market Perform) |
4.50 (10.19) |
126.44% | Details | |
| 10/13/2025 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2025 | Karyopharm Therapeutics | KPTI | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/1/2025 | Nanobiotix S.A | NBTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/29/2025 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2025 | Replimune Group | REPL | Downgrade | Market Perform (Outperform) |
12.33 (4.50) |
-63.5% | Details | |
| 7/22/2025 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2025 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2025 | Genmab A/S | GMAB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/13/2025 | Genmab A/S | GMAB | Upgrade | Outperform (Market Perform) |
19.69 (25.27) |
28.34% | Details | |
| 2/12/2025 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2024 | Genmab A/S | GMAB | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/31/2024 | Bicycle Therapeutics | BCYC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/8/2024 | Vincerx Pharma | VINC | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2024 | Molecular Partners | MOLN | New Coverage | Outperform (N/A) |
5.02 (3.82) |
-23.9% | Details | |
| 12/8/2023 | Nanobiotix S.A | NBTX | New Coverage | Outperform (N/A) |
5.96 (36.27) |
508.56% | Details | |
| 8/4/2023 | NovoCure Ltd. | NVCR | New Coverage | Outperform (N/A) |
29.10 (14.28) |
-50.93% | Details | |
| 12/7/2022 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Calithera Biosciences | CALA | Downgrade | Market Perform (Outperform) |
2.61 (0.00) |
-100% | Details | |
| 1/20/2022 | Calithera Biosciences | CALA | Upgrade | Outperform (Market Perform) |
0.49 (0.00) |
-100% | Details | |
| 12/14/2021 | Immatics | IMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/30/2021 | Immunogen Inc. | IMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/1/2021 | Vincerx Pharma | VINC | New Coverage | Outperform (N/A) |
13.97 (0.10) |
-99.28% | Details | |
| 10/21/2021 | TCR2 Therapeutics | TCRR | Downgrade | Market Perform (Outperform) |
7.88 (1.48) |
-81.22% | Details | |
| 8/6/2021 | Karyopharm Therapeutics | KPTI | Downgrade | Market Perform (Outperform) |
7.82 (9.02) |
15.35% | Details | |
| 5/3/2021 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2021 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2021 | Immatics | IMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2021 | Calithera Biosciences | CALA | Downgrade | Market Perform (Outperform) |
4.91 (0.00) |
-100% | Details | |
| 11/5/2020 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2020 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2020 | Genmab A/S | GMAB | New Coverage | Market Perform (N/A) |
35.02 (19.69) |
-43.77% | Details | |
| 8/11/2020 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2020 | Calithera Biosciences | CALA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/27/2020 | Immatics | IMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2020 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Adaptimmune Therapeutics plc | ADAP | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/29/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/20/2020 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2020 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/17/2019 | Immunogen Inc. | IMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/24/2019 | Immunogen Inc. | IMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 9/4/2019 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2019 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/15/2019 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2019 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/15/2019 | ArQule | ARQL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2019 | Zai Lab | ZLAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2019 | Adaptimmune Therapeutics plc | ADAP | Downgrade | Market Perform (Outperform) |
4.64 (0.05) |
-98.92% | Details | |
| 3/12/2019 | Trillium Therapeutics | TRIL | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/14/2018 | Mersana | MRSN | Upgrade | Outperform (Market Perform) |
6.04 (8.87) |
46.85% | Details | |
| 10/12/2018 | Immune Design | IMDZ | Downgrade | Market Perform (Outperform) |
2.83 (5.85) |
106.71% | Details | |
| 10/3/2018 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2018 | Replimune Group | REPL | New Coverage | Outperform (N/A) |
16.91 (12.33) |
-27.08% | Details |
